Allergy/Imm Medical News about Daclizumab

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Disengaging the IL-2 Receptor with Daclizumab Enhances IL-7–Mediated Proliferation of CD4+ and CD8+ T Cells
American Journal of Transplantation, 09/29/09

Monti P et al. – In addition, treatment with Daclizumab delays the internalization of CD127 upon IL–7 treatment, retaining T–cell sensitivity to IL–7 for a prolonged time. This effect of Daclizumab highlights the redundancy of the cytokine system, which may influence T–cell proliferation in transplanted patients, and provides information to improve future immunosuppressive strategies.

<< Previous
Symmetric Atrophy of Bilateral Distal Upper Extremities and...

Next >>
Cross-reactive immunity to Mycobacterium tuberculosis...